Mangalam Drugs and Organics Ltd
NSE:MANGALAM
Cash Flow Statement
Cash Flow Statement
Mangalam Drugs and Organics Ltd
| Mar-2021 | Sep-2021 | Mar-2022 | Sep-2022 | Mar-2023 | Sep-2023 | Mar-2024 | Sep-2024 | Mar-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | |||||||||||
| Net Income |
395
|
298
|
277
|
213
|
22
|
(202)
|
40
|
208
|
48
|
(225)
|
|
| Depreciation & Amortization |
92
|
97
|
103
|
107
|
110
|
56
|
146
|
153
|
166
|
179
|
|
| Other Non-Cash Items |
81
|
100
|
121
|
123
|
129
|
218
|
132
|
(17)
|
140
|
158
|
|
| Cash Taxes Paid |
93
|
89
|
88
|
73
|
(0)
|
(22)
|
2
|
1
|
1
|
1
|
|
| Cash Interest Paid |
93
|
105
|
112
|
113
|
128
|
67
|
139
|
147
|
149
|
166
|
|
| Change in Working Capital |
(292)
|
(181)
|
(244)
|
(164)
|
134
|
101
|
(46)
|
14
|
72
|
72
|
|
| Cash from Operating Activities |
276
N/A
|
315
+14%
|
257
-18%
|
279
+9%
|
395
+42%
|
173
-56%
|
122
-30%
|
358
+194%
|
426
+19%
|
184
-57%
|
|
| Investing Cash Flow | |||||||||||
| Capital Expenditures |
(314)
|
(388)
|
(277)
|
(235)
|
(279)
|
(140)
|
(179)
|
(185)
|
(202)
|
(193)
|
|
| Other Items |
2
|
2
|
3
|
3
|
57
|
57
|
0
|
3
|
7
|
5
|
|
| Cash from Investing Activities |
(313)
N/A
|
(386)
-23%
|
(273)
+29%
|
(232)
+15%
|
(222)
+4%
|
(83)
+62%
|
(179)
-115%
|
(182)
-2%
|
(195)
-7%
|
(189)
+3%
|
|
| Financing Cash Flow | |||||||||||
| Net Issuance of Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Net Issuance of Debt |
120
|
197
|
141
|
54
|
(39)
|
(15)
|
196
|
(7)
|
(68)
|
143
|
|
| Other |
(93)
|
(105)
|
(112)
|
(113)
|
(128)
|
(67)
|
(139)
|
(147)
|
(149)
|
(166)
|
|
| Cash from Financing Activities |
27
N/A
|
92
+242%
|
30
-68%
|
(59)
N/A
|
(166)
-180%
|
(82)
+51%
|
57
N/A
|
(154)
N/A
|
(217)
-41%
|
(22)
+90%
|
|
| Change in Cash | |||||||||||
| Net Change in Cash |
(10)
N/A
|
21
N/A
|
14
-36%
|
(12)
N/A
|
7
N/A
|
8
+8%
|
(0)
N/A
|
22
N/A
|
14
-36%
|
(27)
N/A
|
|
| Free Cash Flow | |||||||||||
| Free Cash Flow |
(39)
N/A
|
(74)
-89%
|
(20)
+73%
|
44
N/A
|
116
+163%
|
33
-72%
|
(57)
N/A
|
173
N/A
|
224
+29%
|
(9)
N/A
|
|